The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| Study Name on ClinicalTrials.gov (link is external) | Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis |
|---|---|
| Study Drug | JBT-101 |
| Type of Study Drug | Anti-inflammatory |
| Study Title | A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis |
| Study Phase | 2 |
| Study Sponsor | Corbus Pharmaceuticals |
https://www.clinicaltrials.gov/ct2/show/NCT02465450 (link is external) | |
| Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
| Age | 16 Years to 65 Years |